Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Addition of Inotuzumab Ozogamicin to Melphalan Plus Fludarabine Reduced-Intensity Conditioning Regimen of Allogeneic Transplantation in Patients with Acute Lymphoblastic Leukemia and Aggressive Lymphoid Malignancies: A Phase II Prospective Trial

Blood (2024) 144 (Supplement 1): 2124.

https://doi.org/10.1182/blood-2024-203864

Published: 2024

Journal Articles

Ten-Year Results of a Phase II Clinical Trial Evaluating Ipilimumab Plus Lenalidomide Combination after Autologous Hematopoietic Cell Transplantation in Patients with Lymphoma

Joseph E. Jabbour, Denái R. Milton, Alison M. Gulbis, Bofei Wang, Fadi G. Haddad, Celina Ledesma, Richard E. Champlin, Padmanee Sharma, Ken H. Young, Issa F. Khouri

Blood (2024) 144 (Supplement 1): 7250.

https://doi.org/10.1182/blood-2024-203392

Published: 2024

Journal Articles

Safety of Addition of Inotuzumab Ozogamicin (CMC 544) to Bendamustine, Fludarabine, and Rituximab (BFR) Allogeneic Conditioning for Lymphoid Malignancies

Issa F. Khouri, Alison M. Gulbis, Denái R. Milton, Martin Korbling, MD, Celina Ledesma, Sairah Ahmed, Amin M. Alousi, MD, Betul Oran, MDMS, Paolo Anderlini, Stefan O. Ciurea, Roland L. Bassett, Jr., Elias J. Jabbour, MD

Blood (2017) 130 (Supplement 1): 3240.

https://doi.org/10.1182/blood.V130.Suppl_1.3240.3240

Published: 2017

Journal Articles

Bfr (bendamustine, fludarabine, rituximab) Nonmyeloablative Allogeneic Conditioning for Lymphoid Malignancies: 8-Year Results

Issa F. Khouri, Elias J. Jabbour, MD, Celina Ledesma, Martin Korbling, MD, Amin M. Alousi, Paolo Anderlini, Betul Oran, MDMS, Stefan O. Ciurea, Luis E. Fayad, Roland L. Bassett, Jr., Alison M. Gulbis

Blood (2017) 130 (Supplement 1): 2036.

https://doi.org/10.1182/blood.V130.Suppl_1.2036.2036

Published: 2017

Journal Articles

Gemcitabine/Clofarabine/Busulfan: A New Myeloablative Reduced-Toxicity Conditioning Regimen with High Activity for Allogeneic Stem-Cell Transplant (alloSCT) in Aggressive Lymphomas

Yago Nieto, MD PhD, Peter F Thall, Benigno C Valdez, PhD, Junsheng Ma, MS, Melissa Timmons, Michelle Trapp, Sairah Ahmed, MD, Elizabeth J Shpall, MD, Roy B Jones, MDPhD, Chitra Hosing, MD, Paolo Anderlini, Uday Popat, MD, Muzaffar H. Qazilbash, MD, Amin Alousi, MD, Alison M Gulbis, PharmD, Celina Ledesma, Richard E. Champlin, MD, Borje S Andersson, MDPhD

Blood (2017) 130 (Supplement 1): 1966.

https://doi.org/10.1182/blood.V130.Suppl_1.1966.1966

Published: 2017

Journal Articles

Ofatumumab, Very Late Antigen 4 (VLA4), and Dendritic Cells in Patients Undergoing Autologous Peripheral Blood Stem Cell (PBSC) Mobilization and Transplantation (ASCT) for Relapsed b-Cell Non-Hodgkin's Lymphomas (NHL)

Issa F. Khouri, Hui Gao, Denái R. Milton, Martin Korbling, MD, Celina Ledesma, Luis E. Fayad, Elias J. Jabbour, MD, Alison M. Gulbis, James M. Reuben

Blood (2017) 130 (Supplement 1): 1925.

https://doi.org/10.1182/blood.V130.Suppl_1.1925.1925

Published: 2017

Journal Articles

Lenalidomide with Ipilimumab for Lymphoid Malignancies after Allogeneic or Autologous Stem Cell Transplantation (SCT)

Issa F. Khouri, MD, Irina Fernandez Curbelo, PhD, Francesco Turturro, MD, Denái R. Milton, Rang A Kim, Elias J. Jabbour, MD, Roland L Bassett, Jr., Luis M Vence, PhD, Padmanee Sharma, MD PhD, Alison M Gulbis, PharmD

Blood (2016) 128 (22): 1164.

https://doi.org/10.1182/blood.V128.22.1164.1164

Published: 2016

Journal Articles

Ofatumumab Plus Ifosfamide/Etoposide (OIE) Followed By Autologous Stem Cell Transplantation (ASCT) in Patients with b-Cell Non-Hodgkin's Lymphomas (NHL)

Issa F. Khouri, MD, Francesco Turturro, MD, Denái R. Milton, Martin Korbling, MD, Barry I Samuels, BA, MD, Elias J. Jabbour, MD, Celina Ledesma, BS, Rosamar B Valverde, Hui Gao, PhD, Michelle A Fanale, MD, Luis E. Fayad, MD, Loretta J. Nastoupil, MD, James M Reuben, BS, MBA, MS, PhD, Alison M Gulbis, PharmD

Blood (2016) 128 (22): 5814.

https://doi.org/10.1182/blood.V128.22.5814.5814

Published: 2016

Journal Articles

Stratified Intense-Dose- Yttrium-90 Ibritumumab Tiuxetan ( 90 YIT ) with Bendamustine+Fludarabine Nonmyeloablative Conditioning for Allogeneic Stem Cell Transplantation in b-Cell Malignancies

Issa F. Khouri, MD, Bill Erwin, MS, Alison M Gulbis, PharmD, Francesco Turturro, MD, S Cheenu Kappadath, PhD, Dustin Gress, MS, Rosamar B Valverde, Elias J. Jabbour, MD, Roland L Bassett, Jr., Aaron Jessop, MBA,MD

Blood (2016) 128 (22): 662.

https://doi.org/10.1182/blood.V128.22.662.662

Published: 2016

Journal Articles

Bfr (bendamustine, fludarabine, rituximab) Nonmyeloablative Allogeneic Conditioning Improves Survival in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL).

Issa F. Khouri, Rima M Saliba, PhD, Celina Ledesma, Elias J. Jabbour, MD, Francesco Turturro, MD, Gheath Alatrash, DO, PhD, Sairah Ahmed, MD, Betul Oran, MD, Krina K Patel, Amanda Olson, David Marin, MD, Uday R. Popat, MD, Tina S Suki, Jeffrey L. Jorgensen, MD PhD, L. Jeffrey Medeiros, MD, Alison M Gulbis

Blood (2015) 126 (23): 2011.

https://doi.org/10.1182/blood.V126.23.2011.2011

Published: 2015

Journal Articles

In-Vivo Purging with Rituximab (R) Followed By Z/BEAM Vs BEAM/R Autologous Stem Cell Conditioning for Relapsed Diffuse Large B-Cell Lymphoma (DLBCL) Patients (pts): Mature Results from a Combined Analysis of 3 Trials

Blood (2015) 126 (23): 3192.

https://doi.org/10.1182/blood.V126.23.3192.3192

Published: 2015

Journal Articles

Double Epigenetic Modulation of High-Dose Chemotherapy (HDC) with Autologous Stem-Cell Transplant (ASCT) for Patients with Refractory or Poor-Risk Relapsed Lymphoma

Yago Nieto, MD, PhD, Benigno C. Valdez, PhD, Peter F Thall, PhD, Wei Wei, MS, Roy Jones, MD PhD, Chitra M. Hosing, MD, Sairah Ahmed, MD, Uday R. Popat, MD, Elizabeth J. Shpall, MD, Muzaffar Qazilbash, MD, Alison M Gulbis, Paolo Anderlini, MD, Nina Shah, MD, Qaiser Bashir, MD, Amin M. Alousi, MD, Yasuhiro Oki, MD, Fredrick B. Hagemeister, MD, Richard E. Champlin, MD, Borje S. Andersson, MD PhD

Blood (2015) 126 (23): 1992.

https://doi.org/10.1182/blood.V126.23.1992.1992

Published: 2015

Journal Articles

Pentostatin Therapy for Steroid-Refractory Acute Graft Versus Host Disease: Identifying Those Who May Benefit

Brittany Knick Ragon, MD, Alison M Gulbis, Rima M Saliba, PhD, Julianne Chen, Gabriela Rondon, MD, Uday R. Popat, MD, Yago Nieto, MD PhD, Betul Oran, MD, Amanda L. Olson, MD, Krina Patel, MD, Chitra M. Hosing, MD, Muzaffar H. Qazilbash, MD, Nina Shah, MD, Partow Kebriaei, MD, Elizabeth J. Shpall, MD, Richard E. Champlin, MD, Amin M. Alousi, MD

Blood (2015) 126 (23): 3136.

https://doi.org/10.1182/blood.V126.23.3136.3136

Published: 2015

Journal Articles

Ibrutinib in Patients (Pts) with Mantle Cell Lymphoma (MCL) and Chronic Lymphocytic Leukemia (CLL) with Relapsed Disease Post Allogeneic Stem Cell Transplantation (alloSCT)

Issa F. Khouri, Elias Jabbour, Rima M Saliba, PhD, Celina Ledesma, Jan A Burger, MD PhD, Susan O'Brien, MD, Alison M Gulbis

Blood (2015) 126 (23): 4345.

https://doi.org/10.1182/blood.V126.23.4345.4345

Published: 2015

Journal Articles

Outcomes Following Allogeneic Stem Cell Transplantation (AlloSCT) in Patients with Primary Mediastinal (PMBL), Germinal Center B (GCB) and Non-GCB Cell-like Diffuse Large B Cell Lymphomas (DLBCL)

Issa F. Khouri, MD, Rima M Saliba, PhD, Zijun Y. Xu-Monette, PhD, Martin Korbling, MD, Gabriela Rondon, MD, Rosamar Valverde, Amin M. Alousi, MD, Paolo Anderlini, MD, Sairah Ahmed, MD, Stefan O Ciurea, MD, Luis Fayad, MD, Betul Oran, MD, Simrit Parmar, Uday R. Popat, MD, Jason R. Westin, MD, Francesco Turturro, MD, L. Jeffrey Medeiros, MD, Alison M Gulbis, PharmD, BCOP, Ken H. Young, MD PhD

Blood (2014) 124 (21): 2563.

https://doi.org/10.1182/blood.V124.21.2563.2563

Published: 2014

Journal Articles

A Lower Dose Of Melphalan (140 mg/m 2 ) As Preparative Regimen For Multiple Myeloma In Patients >65 Or With Renal Dysfunction

Ila Maewal Saunders, PharmD, Alison M Gulbis, PharmD, BCOP, Richard E Champlin, MD, Muzaffar H. Qazilbash, MD

Blood (2013) 122 (21): 5536.

https://doi.org/10.1182/blood.V122.21.5536.5536

Published: 2013

Journal Articles

Ofatumumab Plus Chemotherapy Followed By G-CSF For Mobilization Of Peripheral Blood Stem Cells (PBSC) In Patients With B-Cell Non-Hodgkin’s Lymphomas (NHL)

Issa F. Khouri, MD, Hui Gao, PhD, Wei Wei, MS, Martin Korbling, MD, Celina Ledesma, BS, Rosamar Valverde, MD, Alison M Gulbis, PharmD, BCOP, James M Reuben, PhD

Blood (2013) 122 (21): 4518.

https://doi.org/10.1182/blood.V122.21.4518.4518

Published: 2013

Journal Articles

Bfr (bendamustine, fludarabine, rituximab) Vs. FCR Nonmyeloablative Allogeneic Conditioning In Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL): Outcome Results Including Minimal Residual Disease Analysis

Issa F. Khouri, MD, Rima M. Saliba, Ph.D., Pramoda Challagundla, Celina Ledesma, Martin Korbling, MD, Alison M Gulbis, PharmD, BCOP, Maria Guillermo-Pacheco, Sairah Ahmed, MD, Paolo Anderlini, MD, Qaiser Bashir, MD, Betul Oran, MD, Stefan O Ciurea, MD, Chitra M. Hosing, MD, Partow Kebriaei, MD, Uday R Popat, MD, Elias Jabbour, MD, Richard E Champlin, MD, Jeffrey L. Jorgensen, MD, PhD

Blood (2013) 122 (21): 3349.

https://doi.org/10.1182/blood.V122.21.3349.3349

Published: 2013

Journal Articles

Outcomes Following Autologous Stem Cell Transplantation (ASCT) In Patients With Germinal Center B (GCB) and Non-GCB Cell-Like Diffuse Large B Cell Lymphomas (DLBCL) According To Conditioning With BEAM-Rituximab (Standard vs. High-Dose) Vs. BEAM/Yttrium-90 Ibritumomab Tiuxetan ( 90 YIT)

Issa F. Khouri, MD, Rima M. Saliba, Ph.D., Zijun Y Xu-Monette, MD, Gabriela Rondon, MD, Rosamar Valverde, MD, Martin Korbling, MD, Alison M Gulbis, PharmD, BCOP, Paolo Anderlini, MD, Ahmed Sairah, MD, Chitra M. Hosing, MD, Uday R Popat, MD, Partow Kebriaei, MD, Luis E Fayad, Jason R. Westin, MD, Francesco Turturro, MD, L. Jeffrey Medeiros, MD, Richard E Champlin, MD, Ken H. Young, MD, PhD

Blood (2013) 122 (21): 3350.

https://doi.org/10.1182/blood.V122.21.3350.3350

Published: 2013

Journal Articles

Modified-CVAD Or Modified-Cbad Compared To High Dose Cyclophosphamide For Peripheral Blood Stem Cell Mobilization In Patients With Multiple Myeloma

Suzanne C Gettys, PharmD, Alison M Gulbis, PharmD, BCOP, Kaci Wilhelm, PharmD, BCOP, Yvonne T Dinh, Gabriela Rondon, MD, Muzaffar H. Qazilbash, MD

Blood (2013) 122 (21): 2036.

https://doi.org/10.1182/blood.V122.21.2036.2036

Published: 2013

NARROW

Addition of Inotuzumab Ozogamicin to Melphalan Plus Fludarabine Reduced-Intensity Conditioning Regimen of Allogeneic Transplantation in Patients with Acute Lymphoblastic Leukemia and Aggressive Lymphoid Malignancies: A Phase II Prospective Trial

Ten-Year Results of a Phase II Clinical Trial Evaluating Ipilimumab Plus Lenalidomide Combination after Autologous Hematopoietic Cell Transplantation in Patients with Lymphoma

Safety of Addition of Inotuzumab Ozogamicin (CMC 544) to Bendamustine, Fludarabine, and Rituximab (BFR) Allogeneic Conditioning for Lymphoid Malignancies

Bfr (bendamustine, fludarabine, rituximab) Nonmyeloablative Allogeneic Conditioning for Lymphoid Malignancies: 8-Year Results

Gemcitabine/Clofarabine/Busulfan: A New Myeloablative Reduced-Toxicity Conditioning Regimen with High Activity for Allogeneic Stem-Cell Transplant (alloSCT) in Aggressive Lymphomas

Ofatumumab, Very Late Antigen 4 (VLA4), and Dendritic Cells in Patients Undergoing Autologous Peripheral Blood Stem Cell (PBSC) Mobilization and Transplantation (ASCT) for Relapsed b-Cell Non-Hodgkin's Lymphomas (NHL)

Lenalidomide with Ipilimumab for Lymphoid Malignancies after Allogeneic or Autologous Stem Cell Transplantation (SCT)

Ofatumumab Plus Ifosfamide/Etoposide (OIE) Followed By Autologous Stem Cell Transplantation (ASCT) in Patients with b-Cell Non-Hodgkin's Lymphomas (NHL)

Stratified Intense-Dose- Yttrium-90 Ibritumumab Tiuxetan ( 90 YIT ) with Bendamustine+Fludarabine Nonmyeloablative Conditioning for Allogeneic Stem Cell Transplantation in b-Cell Malignancies

Bfr (bendamustine, fludarabine, rituximab) Nonmyeloablative Allogeneic Conditioning Improves Survival in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL).

In-Vivo Purging with Rituximab (R) Followed By Z/BEAM Vs BEAM/R Autologous Stem Cell Conditioning for Relapsed Diffuse Large B-Cell Lymphoma (DLBCL) Patients (pts): Mature Results from a Combined Analysis of 3 Trials

Double Epigenetic Modulation of High-Dose Chemotherapy (HDC) with Autologous Stem-Cell Transplant (ASCT) for Patients with Refractory or Poor-Risk Relapsed Lymphoma

Pentostatin Therapy for Steroid-Refractory Acute Graft Versus Host Disease: Identifying Those Who May Benefit

Ibrutinib in Patients (Pts) with Mantle Cell Lymphoma (MCL) and Chronic Lymphocytic Leukemia (CLL) with Relapsed Disease Post Allogeneic Stem Cell Transplantation (alloSCT)

Outcomes Following Allogeneic Stem Cell Transplantation (AlloSCT) in Patients with Primary Mediastinal (PMBL), Germinal Center B (GCB) and Non-GCB Cell-like Diffuse Large B Cell Lymphomas (DLBCL)

A Lower Dose Of Melphalan (140 mg/m 2 ) As Preparative Regimen For Multiple Myeloma In Patients >65 Or With Renal Dysfunction

Ofatumumab Plus Chemotherapy Followed By G-CSF For Mobilization Of Peripheral Blood Stem Cells (PBSC) In Patients With B-Cell Non-Hodgkin’s Lymphomas (NHL)

Bfr (bendamustine, fludarabine, rituximab) Vs. FCR Nonmyeloablative Allogeneic Conditioning In Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL): Outcome Results Including Minimal Residual Disease Analysis

Outcomes Following Autologous Stem Cell Transplantation (ASCT) In Patients With Germinal Center B (GCB) and Non-GCB Cell-Like Diffuse Large B Cell Lymphomas (DLBCL) According To Conditioning With BEAM-Rituximab (Standard vs. High-Dose) Vs. BEAM/Yttrium-90 Ibritumomab Tiuxetan ( 90 YIT)

Modified-CVAD Or Modified-Cbad Compared To High Dose Cyclophosphamide For Peripheral Blood Stem Cell Mobilization In Patients With Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only